Tamoxifen therapy benefit for patients with 70-gene signature high and low risk.

about

Association of 70-Gene Signature Assay Findings With Physicians' Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay.

P2860

Q45071124-7B5AD8AF-8E95-4398-8FA6-2FF042445770

P2860

Tamoxifen therapy benefit for patients with 70-gene signature high and low risk.

Item

http://www.wikidata.org/entity/Q44296908

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Tamoxifen therapy benefit for patients with 70-gene signature high and low risk.

@en

Tamoxifen therapy benefit for patients with 70-gene signature high and low risk.

@nl

type

Item

label

Tamoxifen therapy benefit for patients with 70-gene signature high and low risk.

@en

Tamoxifen therapy benefit for patients with 70-gene signature high and low risk.

@nl

prefLabel

Tamoxifen therapy benefit for patients with 70-gene signature high and low risk.

@en

Tamoxifen therapy benefit for patients with 70-gene signature high and low risk.

@nl

P1476

Tamoxifen therapy benefit for patients with 70-gene signature high and low risk.

@en

P2093

Bo Nordenskjöld

http://www.w3.org/2001/XMLSchema#string

Christina Yau

http://www.w3.org/2001/XMLSchema#string

Christopher C Benz

http://www.w3.org/2001/XMLSchema#string

Laura J Esserman

http://www.w3.org/2001/XMLSchema#string

Laura J van 't Veer

http://www.w3.org/2001/XMLSchema#string

Linda Sofie Lindström

http://www.w3.org/2001/XMLSchema#string

Olle Stål

http://www.w3.org/2001/XMLSchema#string

Tommy Fornander

http://www.w3.org/2001/XMLSchema#string

P2860

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Gene expression profiling predicts clinical outcome of breast cancer

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects.

Status of adjuvant endocrine therapy for breast cancer.

A breast cancer gene signature for indolent disease.

Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901.

P2888

s10549-017-4428-9

P304

593-601

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10549-017-4428-9

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

166

http://www.w3.org/2001/XMLSchema#string

P50

Nancy Y Yu

P577

2017-08-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28776283

http://www.w3.org/2001/XMLSchema#string

P932

5668340

http://www.w3.org/2001/XMLSchema#string

Tamoxifen therapy benefit for patients with 70-gene signature high and low risk.

about

P2860

P2860

Tamoxifen therapy benefit for patients with 70-gene signature high and low risk.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932